Innovation is the key to the future. This is true for many industries including the healthcare industry. New medicines and treatments that have yet to be invented or discovered will be needed to continue improving the quality of life for those inflicted by medical issues. Jeff Aronin, a major pharmaceutical CEO, has been on the forefront of this effort to create new medications for ailments plaguing people all over the world.
Jeff Aronin recognized by medical industry magazine
Aronin is CEO of Paragon Biosciences and was recently named one of the 20 most influential leaders in the healthcare industry for 2018 by Insights Care magazine. Paragon is a bioscience venture incubator which invests in and helps new venture biotechnology companies. The company currently leads the industry with more than 32 New and Novel Drug Approvals that have been earned by Paragon’s portfolio companies and the talented staff on Paragon’s research and development teams.
Paragon to invest $445 million in capital
Paragon, under the leadership of Jeff Aronin, focuses on developing pharmaceutical compounds used to treat a variety of ailments. Since October 2017, the pharmaceutical venture company has invested more than $450 million into biopharmaceutical companies that have experienced high rates of growth. Some of the companies in Paragon’s portfolio includes Emalex Biosciences, Castle Creek Pharma and Harmony Biosciences. Within the next year Paragon is planning on investing at least another $445 million into various aspects of its business model.
Leadership and making a difference
Aronin believes much of his success in business stems from essential leadership principles. This includes a knack for recruiting and retaining the best talent to create a team that shares the same vision as Paragon’s CEO. Many of Paragon’s staff have stayed with Aronin for more than 15 years. However, according to Aronin, what keeps him most motivated is knowing that he is helping to eliminate human suffering by making a difference in the lives of patients in need.